The CHMP’s positive opinion on ocrelizumab for children aged 10 and older with relapsing multiple sclerosis, announced September 18, puts the therapy one European Commission decision away from its second major regulatory milestone in four months. The FDA approved the same indication in May 2026, making ocrelizumab the second disease-modifying therapy with a sanctioned label for pediatric relapsing MS in the United States, after fingolimod. A positive CHMP opinion almost always converts to a Commission authorization, typically within two months of the committee’s recommendation.
What makes the pediatric extension worth watching is how different it is from Ocrevus’s adult origin story. When the FDA approved ocrelizumab in March 2017, the headline was primary progressive MS, a form of the disease with almost no approved options at the time. The pediatric RMS label carries no such novelty claim, but it addresses a population where treatment options remain limited and where earlier intervention, before accumulated disability compounds, matters clinically. Children and adolescents with relapsing MS are not a large commercial segment, but approvals in younger patients often anchor long-term brand relationships that extend decades into adulthood.
The trial design underlying the CHMP recommendation used weight-based dosing to translate the adult IV regimen to patients as young as 10 weighing at least 25 kg. That threshold matters practically: it defines which newly diagnosed pediatric patients a neurologist can immediately consider for the drug versus those who age or grow into eligibility. The EMA label, once issued by the European Commission, will specify those parameters for EU prescribers, and alignment with the FDA’s weight cutoff would simplify cross-market clinical guidance.
For trial teams, the more immediate consequence is site readiness. EU sites that enrolled pediatric patients in the supporting studies should expect label-driven demand to follow the Commission decision, likely before year-end. Sites without existing pediatric neurology infrastructure will need it before they can participate in any post-approval safety or registry work Roche runs under the new indication.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
